Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

Journal:
The Lancet
Published:
Affiliations:
29
Authors:
30
Institutions Authors Share
Johnson & Johnson, United States of America (USA)
8.000000
0.27
non-affiliated author contributions, Germany
2.000000
0.07
Dermatologie Mahlow, Germany
1.000000
0.03
Oregon Medical Research Center (OMRC), United States of America (USA)
1.000000
0.03
Hospital Italiano de Buenos Aires, Argentina
1.000000
0.03
Miami Dermatology & Laser Research, United States of America (USA)
1.000000
0.03
Hospital Clinic of Barcelona, Spain
1.000000
0.03
University Hospital of Münster (UKM), WWU, Germany
1.000000
0.03
Wallace Skin and Body Institute, United States of America (USA)
1.000000
0.03
Janssen Vaccines and Prevention B.V., Netherlands
1.000000
0.03
Henry Ford Health System (HFHS), United States of America (USA)
1.000000
0.03
Innovaderm Research Inc., Canada
1.000000
0.03
Teikyo University, Japan
1.000000
0.03
Fachklinik Bad Bentheim, Germany
1.000000
0.03
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)
1.000000
0.03
University of California, Los Angeles (UCLA), United States of America (USA)
1.000000
0.03
University of São Paulo (USP), Brazil
1.000000
0.03
University Medical Center Schleswig-Holstein - Campus Kiel (UKSH Kiel), Germany
1.000000
0.03
University of Toronto (U of T), Canada
0.833333
0.03
McMaster University, Canada
0.500000
0.02
Dermatrials Research Inc., Canada
0.500000
0.02
York Dermatology Clinic and Research Center, Canada
0.500000
0.02
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Spain
0.500000
0.02
Francisco de Vitoria University (UFV), Spain
0.500000
0.02
Alliance Clinical Trials Inc., Canada
0.333333
0.01
Probity Medical Research Inc. (PMR), Canada
0.333333
0.01